Marcelo Costa, MD
Marcelo Costa, MD, is a Board-Certified Gastroenterologist/Hepatologist with more than 25 years of experience in managing patients with diverse liver diseases, including Hep B, Hep C, MASH (formerly NASH), autoimmune and biliary disorders, liver fibrosis, cirrhosis, portal hypertension, hepatocellular carcinoma and liver transplantation.
He has a robust leadership track record in pharma R&D, drug development and medical affairs (virology and metabolism therapeutic areas) in HCV, MASH, liver fibrosis and cirrhosis indications. His experience includes HCV protease inhibitors, RORγt oral inhibitors, SSAO/VAP-1 inhibitors and sGC activators. He has also worked in in-license business development teams that successfully resulted in development programs for a novel SSAO/VAP-1 inhibitor PXS-4728 from Pharmaxis, an siRNA HMGB1 inhibitor from Dicerna and a first-in-class IL-11 inhibitor antibody from Enleofen.
Dr. Costa has a particular interest in the development of non-invasive tests (biomarkers, -omics and imaging) for patient screening, assessment of disease severity and treatment response to support both daily practice and clinical trial settings.
After joining Fortrea (formerly Labcorp) in 2022, Dr. Costa has served as the lead project physician for two Phase II trials in MASH and one Phase II trial in a rare GI/liver disease indication.
